By Chris Wack
Autonomix Medical shares were up 39% to $14.20 after the company said it saw positive results from a clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves to mitigate pain in patients with pancreatic cancer.
The medical device company said the first 15 patients in its ongoing proof-of-concept human clinical trial saw significant reduction in pain and improvement in regards to their pancreatic cancer pain.
Autonomix said it remains on track to complete enrollment by calendar year end.
Through seven days, the post-procedure showed a decrease in opioid demand, with no responding patient needing a dose increase. No responding patient needed opioids after their 24-hour post-procedure follow-up visit.
A total of twenty patients will be enrolled in the trial.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 31, 2024 09:54 ET (13:54 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.